MNOV, US58468P2065

MediciNova stock gained 9.20 percent as MN-001 data split results

Published on 10/04/2026 at 17:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MediciNova stock follows a 40-patient Phase 2 study with a 30.96 mg/dL triglyceride gap at Week 4 on September 28, 2026. Six analysts set a USD 8.3333 average target.

MNOV, US58468P2065, Illustration mit AI erstellt.

MediciNova stock (ISIN US58468P2065) gained 9.20 percent to USD 1.78 on Nasdaq on October 2, 2026, with volume of 274,357 shares. The move followed a mixed clinical update in which MN-001 showed measurable metabolic benefits but missed statistical significance on the liver-fat endpoint.

MN-001 delivers mixed signals

According to GlobeNewswire on September 28, 2026, the Phase 2 MN-001-NATG-202 study covered 40 patients over 24 weeks. At Week 4, triglycerides fell 30.96 mg/dL more with MN-001 than with placebo, a statistically significant difference with a p-value of 0.015.

The longer-term picture was less decisive. At Week 24, the triglyceride reduction was 31.4 mg/dL greater than placebo but was not statistically significant, while the liver-fat reduction advantage was 9.7 dB/m with a p-value of 0.2438. HDL-C rose 3.3 mg/dL in the MN-001 group and fell 2.4 mg/dL with placebo, producing a statistically significant 5.7 mg/dL difference, according to GlobeNewswire.

Quarterly numbers remain small

MediciNova's latest reported quarter was Q2 2026. Revenue was USD 0.46 million versus a USD 0.07 million consensus, while reported EPS was negative USD 0.05 against a negative USD 0.06 estimate, according to MarketBeat. The revenue beat was larger in relative terms than the earnings improvement, but the absolute revenue base remains limited for a clinical-stage biotechnology company.

The company is concentrating development on MN-166, or ibudilast, for neurological and inflammatory diseases and MN-001, or tipelukast, for metabolic and fibrotic disorders. The September 28 trial release described treatment-related adverse events as mild to moderate and reported zero drug-related serious adverse events, while also stating that a larger study is needed.

Analyst targets stay above price

MarketBeat reported a Moderate Buy consensus from six analysts on September 14, 2026, with three Buy ratings, one Strong Buy, one Hold and one Sell. The average 12-month price target was USD 8.3333, which lies 368.16 percent above the October 2 price of USD 1.78.

That gap highlights the binary nature of the story: clinical validation could matter more than near-term revenue, while the statistically mixed Week 24 data leave the next development step as a central valuation issue. Yahoo Finance lists November 12, 2026, as the estimated next earnings date.

MediciNova stock remains below yearly high

MediciNova stock closed at USD 1.78 on Nasdaq on October 2, 2026. Its 52-week range was USD 1.17 to USD 3.90, while market capitalization stood at USD 87.6 million.